MAPT and Alzheimer disease: Recent research suggests the pattern of tau phosphorylation, rather than levels at individual phosphorylation sites, may play a critical role in the heterogeneity observed in clinical symptoms of AD patients (Dujardin et al., 2020; Wesseling et al., 2020).